1.88
price up icon3.30%   0.06
after-market 시간 외 거래: 1.88
loading
전일 마감가:
$1.82
열려 있는:
$1.84
하루 거래량:
2.00M
Relative Volume:
1.12
시가총액:
$410.18M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-3.6154
EPS:
-0.52
순현금흐름:
$-23.38M
1주 성능:
+5.03%
1개월 성능:
+14.63%
6개월 성능:
+70.91%
1년 성능:
+89.90%
1일 변동 폭
Value
$1.805
$1.8995
1주일 범위
Value
$1.75
$1.8995
52주 변동 폭
Value
$0.80
$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
명칭
Akebia Therapeutics Inc
Name
전화
617-871-2098
Name
주소
245 FIRST STREET, CAMBRIDGE, MA
Name
직원
167
Name
트위터
@akebiatx
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
AKBA's Discussions on Twitter

AKBA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
AKBA 1.88 410.18M 194.75M -51.26M -23.38M -0.52
ZTS 176.96 79.84B 9.15B 2.43B 2.31B 4.92
HLN 9.65 43.63B 14.26B 1.55B 0 0.3327
TAK 13.38 42.42B 30.27B 1.93B 3.45B 0.444
TEVA 17.12 19.40B 16.77B -959.00M 1.37B -2.00
VTRS 13.37 15.96B 15.05B -883.30M 1.89B 1.53

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-03-31 다운그레이드 H.C. Wainwright Buy → Neutral
2022-03-31 다운그레이드 Mizuho Buy → Neutral
2022-03-31 다운그레이드 Needham Buy → Hold
2022-03-31 다운그레이드 Piper Sandler Overweight → Neutral
2021-03-08 개시 Cantor Fitzgerald Overweight
2021-01-29 다운그레이드 JP Morgan Neutral → Underweight
2019-11-14 재확인 Needham Buy
2019-08-06 재확인 H.C. Wainwright Buy
2019-07-11 재확인 H.C. Wainwright Buy
2019-05-02 개시 JP Morgan Overweight
2019-03-20 개시 Citigroup Neutral
2018-09-07 재개 Morgan Stanley Equal-Weight
2018-08-10 재확인 Needham Buy
2018-06-06 재확인 H.C. Wainwright Buy
2017-12-19 개시 Piper Jaffray Overweight
2017-12-07 개시 BTIG Research Buy
2017-09-15 개시 RBC Capital Mkts Sector Perform
2017-07-10 재확인 H.C. Wainwright Buy
2017-04-27 재확인 H.C. Wainwright Buy
2017-04-27 재확인 Needham Buy
2016-12-27 재확인 H.C. Wainwright Buy
2016-12-20 재확인 JMP Securities Mkt Outperform
2016-11-15 개시 Aegis Capital Buy
2016-09-29 개시 Brean Capital Buy
2016-03-16 재확인 Needham Buy
2016-01-21 개시 Credit Suisse Neutral
모두보기

Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스

pulisher
Nov 23, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - GuruFocus.com

Nov 23, 2024
pulisher
Nov 23, 2024

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com

Nov 23, 2024
pulisher
Nov 23, 2024

Vadadustat Alternative Dosing Study Results Published in the Ame - GuruFocus.com

Nov 23, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Resul - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply C - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - GuruFocus.com

Nov 22, 2024
pulisher
Nov 20, 2024

Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 14, 2024

Akebia's FDA-Approved Vafseo Shows Promise in Key Dialysis Trial Results | AKBA Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World

Nov 13, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Prepares for Vafseo Launch - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow

Nov 07, 2024
pulisher
Nov 06, 2024

Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN

Nov 06, 2024
pulisher
Nov 04, 2024

Akebia Therapeutics to present at upcoming investor conferences - MSN

Nov 04, 2024
pulisher
Nov 02, 2024

Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz

Nov 01, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World

Oct 31, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Oct 31, 2024
pulisher
Oct 29, 2024

EasyA x Polkadot Hackathon startup lands a spot at Y Combinator - Investing.com

Oct 29, 2024
pulisher
Oct 25, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 25, 2024
pulisher
Oct 23, 2024

Akebia stock climbs 8% on dialysis provider supply agreement - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

High Growth Tech Stocks to Watch in October 2024 - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St

Oct 23, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance

Oct 22, 2024
pulisher
Oct 17, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne

Oct 17, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Oct 16, 2024

Akebia Therapeutics Inc (AKBA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$90.52
price up icon 3.66%
$13.36
price down icon 0.30%
$85.69
price up icon 0.28%
$60.98
price up icon 2.21%
$125.65
price up icon 0.52%
$13.37
price up icon 0.91%
자본화:     |  볼륨(24시간):